Navigation Links
Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study
Date:1/31/2008

AMSTERDAM, January 31 /PRNewswire/ -- Oncology focused biopharmaceutical product development company Kiadis Pharma announced today that it has successfully finalized its Rhitol(TM) Phase II clinical trial with the last patient completing its six month treatment cycle. Rhitol(TM) is evaluated as treatment for patients with extensive chronic Graft versus Host Disease (GvHD) intolerant or resistant to standard immunosuppressive treatment.

The current preliminary clinical results demonstrate an excellent safety profile for Rhitol(TM) and evidence of efficacy in the alleviation of the symptoms associated with chronic Graft versus Host Disease. After this clinical study was closed for enrollment mid 2007 Kiadis Pharma allowed new patients to be treated under a compassionate protocol. The successful completion of the Phase II clinical trial of Rhitol(TM) paves the way for a phase III study and Kiadis Pharma is planning to file for a phase III multi center clinical trial in the USA and Canada within the next few months.

Manja Bouman, CEO Kiadis Pharma comments: "We are very pleased with the positive outcome of this study and the potential shown by Rhitol(TM). This product would fulfill a significant unmet medical need since patients with chronic GvHD resistant or intolerant to immunosuppressive drugs have no other standard treatment option available to them and this disease can subsequently develop into a life-threatening condition."

To read the complete press releases please go to http://www.kiadis.com

English release is provided by Kiadis Pharma. Equivalent translations are from a third party.


'/>"/>
SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Kiadis Pharma Announces ATIR Interim Clinical Results
2. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
3. Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
4. Kiadis Pharma Presents ATIR and Rhitol Data at ASH and NIH Presentation on ATIR at ASH
5. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
6. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of several ... had left education officials with a number of critical issues to address before students ... to be accomplished with little or no disruption to class schedules. Second, the project ...
(Date:5/24/2017)... ... 24, 2017 , ... In modern research, success depends greatly ... for research and understanding the basic principles that were designed to drive that ... in stereo microscopy for brightfield and fluorescence typically used in laboratories working on ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Altec ... its participation in nVerge 2017 – a one-day technology conference in San Diego, CA. ... management solution, which allows users to fully utilize and enhance their Sage ERP solutions ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. Nicholas Rallis and ... now spent 10 years as clinical instructors for the reputable Full Mouth Rehabilitation ... Through the program, private practitioners receive cutting-edge clinical training and learn how to ...
(Date:5/24/2017)... OH (PRWEB) , ... May 24, 2017 , ... Patients ... in Cortland, OH, can now meet with Dr. Joseph Bedich for a consultation, with ... while simultaneously improving their oral health and functionality. , Dr. Bedich offers ...
Breaking Medicine News(10 mins):
(Date:5/12/2017)...  The China and Canada joint tech ... water, energy and detergent, and features a powerful disinfection process. ... washing machine that washes and sanitizes women,s panties or babies, cloth ... ... does not require an external water inlet. ...
(Date:5/10/2017)... Mass., May 10, 2017 Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended April 1, ... of $1.84 increased 666.7% compared to the prior year ... resulted in a significant gain, while non-GAAP diluted EPS ... 3.2%, or 3.8% in constant currency terms.  Excluding the ...
(Date:5/10/2017)... , May 10, 2017  The Corporate ... or employees of sleep therapy clinics to call ... sleep therapy clinic is involved in a substantial ... interested in hearing from an employee of a ... in a kickback scheme to provide medical practice groups ...
Breaking Medicine Technology: